Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS [Yahoo! Finance]
Rigel Pharmaceuticals, Inc. (RIGL)
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rigel.com
Company Research
Source: Yahoo! Finance
on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to R289 for the treatment of patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R289 , Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, is being studied in an ongoing Phase 1b study evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients with LR-MDS who are relapsed or refractory to prior therapies. "We are pleased that R289 has been granted Fast Track designation, which underscores the significant unmet need for patients with transfusion dependent lower-risk MDS," said Raul Rodriguez , Rigel's president and CEO. "By targeting inflammatory signaling, we believe that R289 has the potential to meaningfully improve the lives of those living with this disease." "Lower-risk MDS affects a primarily elderly patient population that faces progressive cytope
Show less
Read more
Impact Snapshot
Event Time:
RIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RIGL alerts
High impacting Rigel Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RIGL
News
- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at Cantor Fitzgerald from $15.00 to $25.00. They now have a "neutral" rating on the stock.MarketBeat
- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.MarketBeat
- Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance
- Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and ExpositionPR Newswire
- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at B. Riley from $17.00 to $27.00. They now have a "neutral" rating on the stock.MarketBeat
RIGL
Earnings
- 11/7/24 - Beat
RIGL
Sec Filings
- 12/9/24 - Form 8-K
- 11/26/24 - Form 4
- 11/26/24 - Form 4
- RIGL's page on the SEC website